Survival of Bifidobacterium animalis subsp. lactis OPB-1 in the Gastrointestinal Tract after its Administration in a Milk-free Soybean Product and the Effect on Fecal Microbiota in Healthy Adults
Abstract:The survival of Bifidobacterium animalis subsp. lactis OPB-1 in the gastrointestinal tract after its administration in a milk-free yogurt-like soybean product and effects on fecal microbiota in humans were determined. Twelve healthy volunteers were administered 100 g of yogurt-like soybean product for 3 weeks. The plate count method combined with specific PCR and quantitative real-time PCR were used to estimate the numbers of total Bifidobacterium and B. animalis subsp. lactis in fecal samples. B. animalis sub… Show more
“…lactis proliferates in the human intestine following ingestion, although the intestinal portion where B. animalis ssp. lactis grew was not precisely indicated in previous studies (Matsumoto 2000;Ishizuka et al 2012;Watanabe and Isono 2012). Our study indicated that this remarkable proliferation of B. animalis ssp.…”
Section: Discussioncontrasting
confidence: 76%
“…lactis grew was not precisely indicated in previous studies (Matsumoto ; Ishizuka et al. ; Watanabe and Isono ). Our study indicated that this remarkable proliferation of B. animalis ssp.…”
Bifidobacterium animalis ssp. lactis GCL2505 has been shown to proliferate in the human intestine. The intestinal dynamics and physiological effects of GCL2505 as well as the mechanism underlying proliferation in the gut were investigated. GCL2505 showed markedly higher resistance to free bile acids (cholic and deoxycholic acids) than other bifidobacterial species. The intestinal dynamics of GCL2505 and B. longum ssp. longum JCM1217T was compared. The level of B. animalis ssp. lactis in the GCL2505‐administered group was remarkably higher than that of B. longum in the JCM1217T‐administered group. The distribution of B. animalis ssp. lactis through the intestine of the GCL2505‐administered group revealed that GCL2505 proliferated in the cecum. The physiological effects of GCL2505 and JCM 1217T were investigated. The cecal IgA level in the GCL2505‐administered group was significantly higher than that in the nontreated control group. In contrast, the JCM 1217T‐administered group did not manifest any change in the cecal IgA level. Mucin excretion in the GCL2505‐administered group was significantly higher than that in the JCM 1217T‐administered group. The thickness of the sulfomucin layer of the colon in the GCL2505‐administered group tended to be higher than that in the JCM 1217T‐administered group. In a loperamide‐induced constipation model, fecal excretion in the GCL2505‐administered group was significantly increased compared with that in the loperamide‐treated control group. Short‐chain fatty acid concentration in the GCL2505‐administered group was significantly higher than that in the loperamide‐treated control group. These results indicate that the level of proliferation of probiotics in the intestine correlates with the magnitude of host physiological responses, such as IgA production and mucin secretion, which possibly affect gastrointestinal functions such as bowel movement to counteract constipation. GCL2505 exhibits high tolerance to secondary bile acids, which partially explains its higher rate of proliferation in the large intestine.
“…lactis proliferates in the human intestine following ingestion, although the intestinal portion where B. animalis ssp. lactis grew was not precisely indicated in previous studies (Matsumoto 2000;Ishizuka et al 2012;Watanabe and Isono 2012). Our study indicated that this remarkable proliferation of B. animalis ssp.…”
Section: Discussioncontrasting
confidence: 76%
“…lactis grew was not precisely indicated in previous studies (Matsumoto ; Ishizuka et al. ; Watanabe and Isono ). Our study indicated that this remarkable proliferation of B. animalis ssp.…”
Bifidobacterium animalis ssp. lactis GCL2505 has been shown to proliferate in the human intestine. The intestinal dynamics and physiological effects of GCL2505 as well as the mechanism underlying proliferation in the gut were investigated. GCL2505 showed markedly higher resistance to free bile acids (cholic and deoxycholic acids) than other bifidobacterial species. The intestinal dynamics of GCL2505 and B. longum ssp. longum JCM1217T was compared. The level of B. animalis ssp. lactis in the GCL2505‐administered group was remarkably higher than that of B. longum in the JCM1217T‐administered group. The distribution of B. animalis ssp. lactis through the intestine of the GCL2505‐administered group revealed that GCL2505 proliferated in the cecum. The physiological effects of GCL2505 and JCM 1217T were investigated. The cecal IgA level in the GCL2505‐administered group was significantly higher than that in the nontreated control group. In contrast, the JCM 1217T‐administered group did not manifest any change in the cecal IgA level. Mucin excretion in the GCL2505‐administered group was significantly higher than that in the JCM 1217T‐administered group. The thickness of the sulfomucin layer of the colon in the GCL2505‐administered group tended to be higher than that in the JCM 1217T‐administered group. In a loperamide‐induced constipation model, fecal excretion in the GCL2505‐administered group was significantly increased compared with that in the loperamide‐treated control group. Short‐chain fatty acid concentration in the GCL2505‐administered group was significantly higher than that in the loperamide‐treated control group. These results indicate that the level of proliferation of probiotics in the intestine correlates with the magnitude of host physiological responses, such as IgA production and mucin secretion, which possibly affect gastrointestinal functions such as bowel movement to counteract constipation. GCL2505 exhibits high tolerance to secondary bile acids, which partially explains its higher rate of proliferation in the large intestine.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.